Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Deerfield Capital Management

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 50
Average round size
info
The average size of a deal this fund participated in
$60M
Portfolio companies 44
Rounds per year 1.79
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Exits 28
Key employees 22
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Biotechnology
  • Pharmaceutical
  • Medical
  • Medical Device
Summary

The main office of represented VC is situated in the Rosamond. The fund was located in North America if to be more exact in United States.

The overall number of key employees were 22.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Deerfield Capital Management, startups are often financed by OrbiMed, Polaris Partners, Deerfield. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Perceptive Advisors, Redmile Group. In the next rounds fund is usually obtained by Deerfield, Sutter Hill Ventures, OrbiMed.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Health Diagnostics. The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Foundation Medicine, Allogene Therapeutics, Alector.

The higher amount of exits for fund were in 2019. The fund is constantly included in 2-6 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top activity for fund was in 2018. Considering the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this Deerfield Capital Management works on 19 percentage points more the average amount of lead investments.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Deerfield Capital Management:
Typical Co-investors
Deerfield Capital Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Deerfield Capital Management:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Arena Alpha -
Binux Capital California, Saratoga, United States
Blockchange Ventures New York, New York, United States
C.D.S Italy -
German Ventures Bayern, Germany, Munich
Hongji Bike China, Hangzhou, Zhejiang
Leave a Nest Co., Ltd. Japan, Shinjuku
MSouth Equity Partners Atlanta, Georgia, United States
National Association of College Stores Oberlin, Ohio, United States
Richemont Geneva, Geneve, Switzerland
Science Foundation Ireland County Dublin, Dublin, Ireland
Simons Foundation New York, New York, United States
Spring Invest France, Ile-de-France, Paris
Summer Capital Amsterdam, Noord-Holland, The Netherlands
Tinicum New York, New York, United States
University of Pennsylvania Graduate School of Education (GSE) Pennsylvania, Philadelphia, United States
Xuhui Venture Capital China, Shanghai
Zi Mei She China, Guangdong, Shenzhen

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Quartet Health

Health Care
Hospital
Information Technology
Personal Health
Predictive Analytics
$7M02 Dec 2019 New York, New York, United States

GrayBug

Biotechnology
Health Care
Medical
$80M20 Aug 2019 Baltimore, Maryland, United States

Frequency Therapeutics

Biotechnology
Genetics
Medical
$62M23 Jul 2019 Woburn, Massachusetts, United States

Revolution Medicines

Health Care
Life Science
Medical
$100M09 Jul 2019 Redwood City, California, United States

Acutus Medical

Biotechnology
Health Care
Health Diagnostics
Manufacturing
Medical Device
$100M20 Jun 2019 Carlsbad, California, United States

Itamar Medical

Health Care
Medical
Medical Device
$8M18 Jan 2019 Israel, North District, Israel

PQ Bypass

Clinical Trials
Health Care
Medical
Medical Device
$60M08 Jan 2019 Sunnyvale, California, United States

Ribon Therapeutics

Biotechnology
Health Care
Medical Device
Therapeutics
$65M04 Jan 2019 Massachusetts, United States

Cabaletta Bio

Biotechnology
Health Care
Medical
Robotics
Therapeutics
$50M03 Jan 2019 Philadelphia, Pennsylvania, United States
News
GH Research Closes $125M Series B Financing

– GH Research Ireland Ltd is a Dublin, Ireland-based clinical-stage biopharmaceutical company.
– The company closed a $125m Series B funding.
– The round was co-led by RA Capital and RTW Investments, LP, with participation from existing investor BVF Partners, and new backers Acuta Capital Partners, Boxer Capital, Cormorant Asset Management, Deerfield Management Company, Logos Capital, Surveyor Capital (a Citadel company), Venrock Healthcare Capital Partners and Verition Fund Management.

Crossover Health Secures $168 Million in Series D Financing to Fuel Expansion of National Primary Health Service

– Crossover Health has secured $168m in Series D financing led by Deerfield Management Company.
– The capital will be applied to continuing the national expansion of Crossover’s Connected System of Health for employers and payers.
– Crossover Health is a relationship-based, tech-enabled, national healthcare organization that integrates both virtual and in-person care for employers and health plans.
– Goldman Sachs & Co. LLC acted as the exclusive placement agent for the financing and Latham & Watkins LLP served as legal counsel to Crossover Health.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Deerfield Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: